Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Depreciation and Amortization

Last Annual Value

382.01K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Depreciation and Amortization

ANEB · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
382.01K
N/AN/AN/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
1.50M
-4.3%9.4%N/A
364.50K
305.5%171.6%N/A
739.00K
-19.0%6.3%N/A
1.55M
-17.3%3.6%5.6%
1.41M
-2.4%8.1%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
-52.91K
N/AN/AN/A
1.13M
58.0%10.8%N/A
121.00K
-14.9%9.5%40.6%
186.00K
-16.7%-11.6%N/A
21.00K
-33.1%-20.9%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72